Prostaglandins: A new class of aqueous outflow agents

C. B. Toris, C. B. Camras

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

The prostaglandin F(2α) analog, latanoprost, has been approved for the treatment of glaucoma in the United States. This is a new class of glaucoma agents that reduces intraocular pressure by increasing uveosclera outflow. Latanoprost is well tolerated, has few side effects, and maintains its efficacy over time. It is additive to other well established glaucoma medications, including timolol, acetazolamide, epinephrine, and pilocarpine. It has the unusual side effect of darkening the iris color in some patients with concentric heterochromia. This effect seems to be a cosmetic problem only, although further investigations are needed for confirmation.

Original languageEnglish (US)
Pages (from-to)335-355
Number of pages21
JournalOphthalmology Clinics of North America
Volume10
Issue number3
StatePublished - Oct 29 1997

    Fingerprint

ASJC Scopus subject areas

  • Ophthalmology

Cite this